Liquid biopsy firm Lexent Bio has appointed Ted Snelgrove as its chief business officer. In the roll, Snelgrove will work closely with the CEO and the company's board on test launch strategy, commercial team development, and corporate partnering.
Snelgrove's experience in molecular diagnostics includes building and leading the original commercial team for Genomic Health's Oncotype DX product line. He also built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, promoting the firm's Vectra DA for disease management in rheumatology. He was CEO at CellScape, an early player in the NIPT market, served as the oncology/hematology business unit head at Jazz Pharmaceuticals, and held C-Level roles at Counsyl and more recently at Guardant Health.